Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats

Microvasc Res. 2013 May:87:41-9. doi: 10.1016/j.mvr.2013.02.007. Epub 2013 Mar 1.

Abstract

We examined the functional and structural microcirculatory alterations in the brain, skeletal muscle and myocardium of non-diabetic spontaneously hypertensive rats (SHR) and diabetic SHR (D-SHR), as well as the effects of long-term treatment with the angiotensin AT1-receptor antagonist olmesartan and the angiotensin-converting enzyme inhibitor enalapril. Diabetes was experimentally induced by a combination of a high-fat diet with a single low dose of streptozotocin (35 mg/kg, intraperitoneal injection). D-SHR were orally administered with olmesartan (5 mg/kg/day), enalapril (10 mg/kg/day) or vehicle for 28 days, and compared with vehicle-treated non-diabetic SHR or normotensive non-diabetic Wistar-Kyoto rats. The cerebral and skeletal muscle functional capillary density of pentobarbital-anesthetized rats was assessed using intravital fluorescence videomicroscopy. Chronic treatment with olmesartan or enalapril significantly lowered blood pressure and reversed brain functional capillary rarefaction. Brain oxidative stress was reduced to non-diabetic control levels in animals treated with olmesartan or enalapril. Histochemical analysis of the structural capillary density showed that both olmesartan and enalapril increased the capillary-to-fiber ratio in skeletal muscle and the capillary-to-fiber volume density in the left ventricle. Olmesartan and enalapril also prevented collagen deposition and the increase in cardiomyocyte diameter in the left ventricle. Our results suggest that the association between hypertension and diabetes results in microvascular alterations in the brain, skeletal muscle and myocardium that can be prevented by chronic blockade of the renin-angiotensin system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Arterial Pressure / drug effects
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Brain / blood supply*
  • Brain / metabolism
  • Capillaries / drug effects
  • Capillaries / physiopathology
  • Cerebrovascular Circulation / drug effects*
  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / etiology
  • Cerebrovascular Disorders / metabolism
  • Cerebrovascular Disorders / physiopathology
  • Coronary Circulation / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / etiology
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetic Angiopathies / drug therapy*
  • Diabetic Angiopathies / etiology
  • Diabetic Angiopathies / metabolism
  • Diabetic Angiopathies / physiopathology
  • Diet, High-Fat
  • Enalapril / pharmacology*
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism
  • Heart Ventricles / pathology
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Imidazoles / pharmacology*
  • Insulin / blood
  • Leukocyte Rolling / drug effects
  • Male
  • Microcirculation / drug effects*
  • Microscopy, Fluorescence
  • Microscopy, Video
  • Muscle, Skeletal / blood supply
  • Oxidative Stress / drug effects
  • Rats
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Renin-Angiotensin System / drug effects*
  • Streptozocin
  • Tetrazoles / pharmacology*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Blood Glucose
  • Imidazoles
  • Insulin
  • Tetrazoles
  • Streptozocin
  • Enalapril
  • olmesartan